The translational revolution and use of biologics in patients with inflammatory skin diseases - 05/02/15
Abstract |
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.
Le texte complet de cet article est disponible en PDF.Key words : Psoriasis, atopic dermatitis, eczema, biologics, IL-23, TH17, TH2, TH22
Abbreviations used : AMP, AD, CIU, DC, FDA, IL-4R, K16, NB, PDE4
Plan
| Disclosure of potential conflict of interest: J. G. Krueger reports grants paid to his institution from Amgen, Innovaderm, and Kyowa; he has received personal fees from Serono, Biogen Idec, Delenex, AbbVie, Sanofi, Baxter, Xenoport, and Kineta and has received personal fees during the conduct of this study from Novartis, Pfizer, Janssen, Lilly, Merck, Kadmon, Dermira, Boehringer, BMS, and Paraxel. E. Guttman-Yassky is a board member for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, and Leo Pharma; has received consultancy fees from Regeneron, Sanofi Aventis, MedImmune, Celgene, Steifel/GlaxoSmithKline, Celsus, BMS, Amgen, and Drais; and has received research support from Regeneron, Celgene, BMS, and Janssen. S. Noda declares no relevant conflicts of interest. |
Vol 135 - N° 2
P. 324-336 - février 2015 Retour au numéro
Article précédent
- The future of biologics: Applications for food allergy
- Rebecca N. Bauer, Monali Manohar, Anne Marie Singh, David C. Jay, Kari C. Nadeau
- The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
- Tse Wen Chang, Christina Chen, Chien-Jen Lin, Martin Metz, Martin K. Church, Marcus Maurer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?